Ionis Pharmaceuticals stock analysis
Ionis Pharmaceuticals (0JDI) Share Price & Analysis
0JDI Stock Chart & Stats
- Day’s Range
- $27.25 - $28.60
- 52-Week Range
- $27.25 - $86.74
- Previous Close
- $27.60
- Volume
- N/A
- Average Volume (3M)
- 6,378
- Market Cap
- $4.84B
- Enterprise Value
- $7.71B
- Total Cash (Recent Filing)
- $1.88B
- Total Debt (Recent Filing)
- $2.15B
- Price to Earnings (P/E)
- ―
- Beta
- 0.71
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- -1.35
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Revenue Growth
Growing commercial revenue indicates that Ionis is progressing beyond research funding toward a broader product-based earnings model. Continued expansion in sales can improve revenue quality over time, support reinvestment in the pipeline, and increase the company’s participation in future commercial upside.
Positive Late-Stage Pipeline
Positive Phase 3 data for a partnered antisense therapy strengthens confidence in Ionis’s technology platform and development capabilities. If longer-term outcomes and regulatory review remain supportive, the program could generate future milestones, royalties, and a durable presence in kidney disease.
New Approved Products
HIBSAGO approval adds another partnered commercial opportunity and expands Ionis’s exposure to a potentially significant chronic hepatitis B market. The licensing economics allow participation through milestones and royalties while partners provide regulatory and commercial execution capabilities.
Bears Say
Persistent Operating Losses
Deep operating and net losses show that Ionis’s current cost base remains well above the earnings generated by its products, partnerships, and pipeline. Unless revenue growth scales faster than spending, profitability may remain distant and internal funding capacity will stay constrained.
Increasing Cash Burn
Negative operating and free cash flow, combined with a sharp year-over-year increase in burn, raises the company’s ongoing funding requirements. Sustained cash consumption can reduce flexibility to invest across programs, commercial launches, and development opportunities without additional financing.
Slower Launch And Breakeven Delay
The slower TRYNGOLZA launch and delayed cash-flow breakeven indicate that commercialization is taking longer to convert clinical potential into financial returns. Reimbursement friction, limited early repeat prescribing, and program setbacks could prolong losses and increase execution pressure.
0JDI FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
What is Ionis Pharmaceuticals’s market cap?
When is Ionis Pharmaceuticals’s upcoming earnings report date?
How were Ionis Pharmaceuticals’s earnings last quarter?
Is Ionis Pharmaceuticals overvalued?
Does Ionis Pharmaceuticals pay dividends?
What is Ionis Pharmaceuticals’s EPS estimate?
How many shares outstanding does Ionis Pharmaceuticals have?
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Ionis Pharmaceuticals Stock Smart Score
Company Description
Ionis Pharmaceuticals
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brett Monia
- Employees
- 1,480
- Website
- www.ionis.com
- Address
- 2855 Gazelle Court, Carlsbad, CA, 92010, US
Ionis Pharmaceuticals (0JDI) Earnings & Revenues
0JDI Company Deck
0JDI Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, supported by strong revenue growth, accelerating DAWNZERA sales, positive pipeline and regulatory progress, substantial partner contributions and a strong cash position. However, the slower-than-expected TRYNGOLZA launch, reduced 2026 TRYNGOLZA guidance, early reimbursement and repeat-prescribing friction, two Phase III disappointments and the shift in expected cash flow breakeven from 2028 to 2029 were meaningful negatives. Highlights significantly outweighed the lowlights, although management emphasized that TRYNGOLZA execution and the 2027 launch trajectory remain important.
View all GB:0JDI earnings summaries0JDI Net sales Breakdown
- 60.82% R&D
- 39.18% Commercial
0JDI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |












